Ranbaxy gets tentative FDA nod to make, market hypertension treatment drug

MUMBAI (Thomson Financial) - India's Ranbaxy Laboratories Ltd said it received tentative approval from the US Food and Drug Administration to manufacture and market amlodipine besylate tablets of 2.5 mg, 5 mg and 10 mg strengths.

Amlodipine besylate tablets treat hypertension, which can be used either alone or in combination with other anti-hypertensive agents. They are marketed in the US by Pfizer (nyse: PFE - news - people ) as Norvasc.

Total annual market sales for amlodipine besylate tablets were 2.79 bln usd, as per data from IMS in March, Ranbaxy said in a release to the Bombay Stock Exchange.
COPYRIGHT

Copyright AFX News Limited 2007. All rights reserved.

The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.

Neither the Subscriber nor AFX News warrants the completeness or accuracy of the Service or the suitability of the Service as a trading aid and neither accepts any liability for losses howsoever incurred. The content on this site, including news, quotes, data and other information, is provided by AFX News and its third party content providers for your personal information only, and neither AFX News nor its third party content providers shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon.
source:www.forbes.com